The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus pandemic. They are available for free with registration. Note that we have added three critical tables, which are continuously updated:
Enanta Pharmaceuticals Inc. has divulged macrocyclic chalcone-amide compounds acting as non-structural protein 3 (nsp3; PL-pro) (SARS-CoV-2; COVID-19 virus) inhibitors.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ascentage, Belite, Revive.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Almirall, Astrazeneca, Bioarctic, Eisai, Entos, GC, GSK, Moderna, Novel, Roche, Santhera, Shattuck.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: 4D, 4Moving, Actinium, Arcturus, Eli Lilly, Genentech, Longboard, Moderna, Oculis, Pacylex, Prokidney, Sellas, Skye, Surrozen, Tharimmune, Vertex.
Moderna Inc. is gearing up to meet with regulators on the next steps for mRNA-1083, the first combination vaccine for influenza and COVID-19 to succeed in phase III testing, not only demonstrating noninferiority to individually licensed competitor vaccines but also eliciting statistically significant higher immune responses.
Emory University has identified 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
Exevir Bio BV has demonstrated that its antibodies are potent in neutralizing the SARS-CoV-2 variant JN.1, the parental strain of the currently most dominantly circulating variants worldwide.